- Home
- VRTX vs FI Comparison
VRTX vs FI Comparison
Compare VRTX & FI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- FI
- Stock Information
- Founded
- VRTX 1989
- FI 1984
- Country
- VRTX United States
- FI United States
- Employees
- VRTX N/A
- FI N/A
- Industry
- VRTX EDP Services
- FI Business Services
- Sector
- VRTX Technology
- FI Consumer Discretionary
- Exchange
- VRTX Nasdaq
- FI Nasdaq
- Market Cap
- VRTX 104.8B
- FI 120.2B
- IPO Year
- VRTX 1991
- FI 1986
- Fundamental
- Price
- VRTX $484.74
- FI $222.01
- Analyst Decision
- VRTX Buy
- FI Strong Buy
- Analyst Count
- VRTX 25
- FI 25
- Target Price
- VRTX $508.09
- FI $237.96
- AVG Volume (30 Days)
- VRTX 1.4M
- FI 3.1M
- Earning Date
- VRTX 05-05-2025
- FI 04-22-2025
- Dividend Yield
- VRTX N/A
- FI N/A
- EPS Growth
- VRTX N/A
- FI 8.03
- EPS
- VRTX N/A
- FI 5.38
- Revenue
- VRTX $11,020,100,000.00
- FI $20,456,000,000.00
- Revenue This Year
- VRTX $10.65
- FI $4.85
- Revenue Next Year
- VRTX $9.02
- FI $8.93
- P/E Ratio
- VRTX N/A
- FI $41.05
- Revenue Growth
- VRTX 11.66
- FI 7.14
- 52 Week Low
- VRTX $377.85
- FI $145.98
- 52 Week High
- VRTX $519.88
- FI $238.59
- Technical
- Relative Strength Index (RSI)
- VRTX 44.78
- FI 51.93
- Support Level
- VRTX $471.50
- FI $214.28
- Resistance Level
- VRTX $513.98
- FI $224.21
- Average True Range (ATR)
- VRTX 12.35
- FI 4.66
- MACD
- VRTX -4.12
- FI 0.33
- Stochastic Oscillator
- VRTX 27.48
- FI 86.80
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About FI Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.